House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Endocrinology

Primary aldosteronism

Endocrine Society · 2025 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The 2025 Endocrine Society guideline conditionally broadens primary aldosteronism screening to all people with hypertension, with implementation shaped by resources and expertise. It uses aldosterone and renin together, interprets results in their assay and medication context, and links subsequent testing to whether surgery is a realistic and desired option. Treatment is directed at aldosterone excess, with either mineralocorticoid receptor antagonism or adrenalectomy for appropriate lateralizing disease.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Screen using aldosterone and renin in context

  • The guideline suggests screening all individuals with hypertension for primary aldosteronism. This is conditional and depends on available resources, local expertise and health-system capacity; it is not an unconditional mandate. [1]
  • Measure aldosterone and renin in the morning with the patient seated, avoiding dietary sodium restriction in the preceding days. Measure potassium to interpret aldosterone, because low potassium can falsely lower it; if the screen is negative with hypokalaemia, correct potassium and repeat. [1]
  • A typical positive screen requires both suppressed renin with inappropriately high aldosterone and an elevated aldosterone-to-renin ratio. Guidance values are PRA ≤1 ng/mL/hour or direct renin ≤8.2 mU/L, together with aldosterone ≥10 ng/dL by immunoassay or ≥7.5 ng/dL by LC-MS/MS. [1]
  • For immunoassay aldosterone, a ratio above 20 applies when aldosterone is in ng/dL and PRA in ng/mL/hour; a ratio above 70 applies when aldosterone is in pmol/L and direct renin in mU/L. LC-MS/MS ratio thresholds are about 25% lower. Interpret with local assay cutoffs and pretest probability rather than treating these values as universal. [1]
  • Manage interfering medicines according to safety and feasibility; the guideline allows minimal-withdrawal and no-withdrawal approaches. A potentially false-negative screen should be repeated on another day after correcting potassium and, when safe, withholding the relevant interfering drugs. [1]
  • For the false-negative reassessment strategy, the stated withdrawal periods are 4 weeks for MRAs, ENaC inhibitors and other diuretics, and 2 weeks for ACE inhibitors or ARBs, only if safe and feasible. [1]
  • Repeat a negative screen when suspicion remains moderate or high, such as resistant hypertension or hypokalaemia, or when renin is suppressed with immunoassay aldosterone 5–10 ng/dL. Re-screen later if hypertension worsens, hypokalaemia develops or atrial fibrillation occurs without structural heart disease or hyperthyroidism. [1]
  • Beta-blockers and central alpha-2 agonists can suppress renin and cause a false-positive screen; consider repeating after 2 weeks off these drugs when safe and feasible. Chronic kidney disease can also increase false-positive results, so interpret biochemical findings in context. [1]

Choose further testing according to the treatment goal

  • The guideline suggests aldosterone-suppression testing after a positive screen when the probability of lateralizing disease is intermediate and the person wishes to pursue surgical eligibility. It does not require suppression testing for every positive screen. [1]
  • Suppression testing is not recommended with resistant hypertension or hypertension plus hypokalaemia and overt renin-independent aldosterone production: PRA below 0.2 ng/mL/hour or direct renin below 2 mU/L, plus aldosterone above 15 ng/dL by LC-MS/MS or above 20 ng/dL by immunoassay. The concern is false-negative suppression tests. [1]
  • People unwilling or unable to pursue adrenal venous sampling and adrenalectomy may receive an MRA based on the screen without suppression testing. Familial germline hyperaldosteronism also does not require suppression testing; genetic screening is recommended for first-degree relatives and for young-onset disease below age 20. [1]
  • For someone considering surgery, the guideline suggests CT plus adrenal venous sampling to distinguish lateralizing from bilateral secretion. A possible exception is a very likely unilateral adenoma, for example age below 35, marked disease with hypokalaemia and a unilateral CT adenoma larger than 1 cm. [1]

Direct treatment at aldosterone excess

  • The guideline suggests PA-specific treatment. Offer the choice according to lateralization, surgical candidacy and preference: unilateral adrenalectomy is generally for lateralizing disease when surgery is desired; long-term MRA therapy is generally for bilateral or unlocalized disease or when surgery is declined or unsuitable. [1]
  • If blood pressure remains uncontrolled and renin remains suppressed during PA-specific medical treatment, the guideline suggests increasing aldosterone-directed therapy to raise renin from baseline. It sets no fixed renin target, and benefit from this strategy with already-controlled pressure remains uncertain. [1]
  • Spironolactone is conditionally preferred because of cost and availability. Other MRAs are expected to have similar efficacy at equivalent potency and may be preferred to reduce androgen- or progesterone-related adverse effects. Monitor potassium, renal function, renin and blood pressure while titrating. [1]
  • The guideline suggests an MRA rather than amiloride or triamterene for PA-specific treatment. This preference does not apply to situations where spironolactone is contraindicated, including hyperkalaemia, advanced renal impairment or pregnancy, or where another MRA is indicated for a different condition. [1]

Check for cortisol co-secretion with an adrenal adenoma

  • In primary aldosteronism with an adrenal adenoma, the guideline suggests dexamethasone suppression testing. For the overnight test, take dexamethasone 1 mg orally at 23:00–24:00 and measure cortisol at 08:00–09:00; a result above 1.8 micrograms/dL or 50 nmol/L suggests autonomous cortisol secretion and needs further evaluation. [1]
  • With mild autonomous cortisol secretion, consider its implications for lateralization and postoperative care. Measure early morning cortisol after adrenal surgery and prepare for possible glucocorticoid insufficiency. [1]

Limitations and use

  • This summary covers the society’s published recommendations and technical remarks. It does not reproduce all assay conversion tables, suppression-test protocols, medication-withdrawal alternatives, adrenal sampling criteria or MRA dose schedules.
  • Screening thresholds are assay- and unit-dependent, and medication changes must be safe for the individual. A positive screening pattern is not interchangeable with a complete diagnosis or proof of unilateral disease.
  • The recommendations are mostly conditional with low or very low certainty; local expertise, contraindications and patient preferences remain central to applying them.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Primary aldosteronism

    Guideline recommendation text consulted

Original guideline

Publication details

Issuing organisation
Endocrine Society
First published
14 July 2025
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Screen using aldosterone and renin in context
  • Choose further testing according to the treatment goal
  • Direct treatment at aldosterone excess
  • Check for cortisol co-secretion with an adrenal adenoma
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House